Gabbi is a technology company.
Gabbi has raised $5.0M across 2 funding rounds.
Gabbi has raised $5.0M in total across 2 funding rounds.
Gabbi has raised $5.0M in total across 2 funding rounds.
Gabbi's investors include Bread and Butter Ventures, Emmeline Ventures, Ingeborg Investments, SoGal Ventures, Amplo, IA Ventures, Lux Capital, Maveron, OMERS Ventures, Sequoia Capital, Sonder Capital, Susa Ventures.
Gabbi is a healthcare technology company specializing in breast cancer risk assessment and early detection. It offers a clinically validated online tool for personalized risk evaluation, virtual consultations with nurse practitioners, and care coordination to expedite screenings and imaging, primarily serving women in their 20s, 30s, and underserved communities like Hispanic and African American patients.[1][2][3][5] By addressing gaps in traditional screening (which starts at age 50), Gabbi accelerates diagnoses up to seven times faster, partners with health systems, employers, and providers to reduce late-stage cancers, improve outcomes, and lower costs—having raised $4.4M since its 2020 founding in Portland, Oregon.[1][3][5]
Gabbi was founded in 2020 (with some sources noting 2019) by Kaitlin Christine, who lost her mother to late-stage breast cancer in 2013 despite regular mammograms, which failed to detect it after four tests.[1][2][5] At age 24, shortly after, Kaitlin discovered a lump herself and was diagnosed with breast cancer during preventative surgery, fueling her decade-long expertise in hereditary cancer at leading healthcare firms.[5] She launched Gabbi to eradicate late-stage diagnoses through prevention and early detection tools, gaining early traction via incubator funding and investments like from Catalyst by Wellstar, which backs its AI for diverse, underserved groups amid rising breast cancer rates in women under 50.[1][3]
Gabbi rides the digital health and women's health tech waves, particularly oncology tech, amid a 13% rise in breast cancer among women under 50 (2000-2019) and 40% higher mortality risk for those under 40 due to delayed diagnosis.[1][3] Timing aligns with AI advancements in predictive analytics and telehealth, closing access gaps for underserved groups via scalable, equitable tools—part of a 10,853-company digital health ecosystem and 572-firm women's health segment.[1] It influences the landscape by driving earlier interventions, reducing patient leakage, and improving quality scores for partners, potentially transforming outcomes in a market favoring preventive, tech-enabled care over reactive models.[3][5]
Gabbi is poised to scale its AI platform through deeper health system integrations and employer benefits, targeting late-stage cancer elimination via broader screenings for high-risk demographics.[3][5] Trends like AI-driven personalization, rising early-onset cancers, and telehealth expansion will propel growth, especially with recent accelerator funding signaling momentum.[1] Its influence may evolve into a standard for preventive oncology, amplifying impact as datasets grow and disparities narrow—reinforcing Kaitlin's mission to safeguard women's health from the personal tragedies that birthed the company.[5]
Gabbi has raised $5.0M across 2 funding rounds. Most recently, it raised $4.0M Seed in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $4.0M Seed | Bread and Butter Ventures, Emmeline Ventures, Ingeborg Investments, SoGal Ventures | |
| Jun 1, 2021 | $1.0M Seed | Amplo, Bread and Butter Ventures, Emmeline Ventures, IA Ventures, Lux Capital, Maveron, OMERS Ventures, Sequoia Capital, Sonder Capital, Susa Ventures, Union Square Ventures, Anne Wojcicki |